Literature DB >> 22712734

Serological analysis of SEREX-defined medullary breast carcinoma-associated antigens.

Olga Kostianets1, Maksym Shyian, Demidov Sergiy, Stepan Antoniuk, Ivan Gout, Valeriy Filonenko, Ramziya Kiyamova.   

Abstract

Medullary breast carcinoma (MBC) despite anaplastic features and high grade has a good prognosis that can be related to prominent lymphocytic infiltration. We analyzed the frequency of antibody response toward 41 SEREX (serological recombinant expression cloning)-defined MBC antigens in sera of allogeneic MBC patients using serological plaque-spot assay and examined the mRNA expression profile of some antigens in MBC tissues. This preliminary study allowed us to select 18 autoantigens as potential MBC-associated antigens. Further studies in large cohorts of breast cancer patients will be performed for their evaluation as targets for cancer diagnostics or therapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22712734     DOI: 10.3109/07357907.2012.697231

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  3 in total

1.  Autoantibody Response to ZRF1 and KRR1 SEREX Antigens in Patients with Breast Tumors of Different Histological Types and Grades.

Authors:  Lada Dyachenko; Kristina Havrysh; Anita Lytovchenko; Irina Dosenko; Stepan Antoniuk; Valeriy Filonenko; Ramziya Kiyamova
Journal:  Dis Markers       Date:  2016-10-25       Impact factor: 3.434

2.  Identification of New Regulators of Pancreatic Cancer Cell Sensitivity to Oxaliplatin and Cisplatin.

Authors:  Vera Skripova; Ramilia Vlasenkova; Yan Zhou; Igor Astsaturov; Ramziya Kiyamova
Journal:  Molecules       Date:  2022-02-14       Impact factor: 4.411

3.  Immunohistochemical analysis of medullary breast carcinoma autoantigens in different histological types of breast carcinomas.

Authors:  Olga Kostianets; Stepan Antoniuk; Valeriy Filonenko; Ramziya Kiyamova
Journal:  Diagn Pathol       Date:  2012-11-26       Impact factor: 2.644

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.